Insights & Analysis
Practical guidance on PBM audits, federal investigations, compounding defense, DEA enforcement, telehealth compliance, and the regulatory pressures facing pharmacies and providers nationwide.
More articles — Page 27
Page 27 of 31 · 279 articles
Pharmacy Alert: Texas Board of Pharmacy Investigations
Texas pharmacies are facing increasing scrutiny by the Board of Pharmacy, which is working closely with the DEA and other federal…
Safeguarding Independents: HLA Reverses PBM Termination on Appeal
PBMs are huge companies that often use their market power in an abusive and predatory manner. This case study and successful netwo…
Corporate Advice: Asset Deals vs. Stock Deals
In Part One of a three-part series on corporate transactions, we describe preliminary considerations around deal structure. In sub…
HLA's Coffey Appointed by Attorney General
HLA's Nancy Coffey, a former government official and healthcare expert, has been appointed to serve a three-year term as an indepe…
Semaglutide Demand is Skyrocketing: Ozempic Opportunities
As summer approaches, soaring demand for weight-loss drugs like Ozempic, Wegovy, and semaglutide compounded copies, will exacerbat…
Off-Label Prescribing and Dispensing: Ozempic, Wegovy, and Other Medications
Anthony Mahajan delves into the intricacies of off-label prescribing and dispensing for medications such as Ozempic, Wegovy, and R…
Semaglutide Compounding Pharmacies Subject to Increasing Regulatory Threats
Semaglutide compounding pharmacies face regulatory threats as state boards interpret statutes restrictively; Health Law Alliance,…
National Audit Services are No Replacement for Attorney Advice
National audit assistance services cannot provide the legal expertise, subject matter knowledge, or audit leverage that healthcare…
Pennsylvania Board Closes Investigation of HLA Client with No Action
Telemedicine business models may prompt regulatory scrutiny, including board investigations. In this case, HLA's experienced defen…